Corcept Therapeutics
CORTCorcept Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of medications that modulate the effects of the hormone cortisol.
Earnings
Next report
Nov 4, 2026 (in a month)Competitors
By market cap
By revenue growth
By net margin
Profile
Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of medications that modulate the effects of the hormone cortisol. The company leverages its proprietary portfolio of selective cortisol modulators to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its primary value proposition lies in managing hypercortisolism and improving outcomes in various solid tumors and neuromuscular diseases without the adverse effects associated with traditional progesterone receptor binding.
A leading specialist in cortisol modulation with a significant proprietary library of over 1,000 selective cortisol modulators and a commercial presence in the Cushing's syndrome market.
FAQ
- What is Corcept Therapeutics's market cap?
- Corcept Therapeutics (CORT) has a market capitalization of $12.3B and trades on NASDAQ.
- What is Corcept Therapeutics's revenue and profitability?
- Corcept Therapeutics generated $830.8M in trailing twelve-month revenue with net income of $55.2M, representing a net margin of 6.6%. Gross margin stands at 98.3%, with free cash flow of $106.9M. The latest reported period is Q2 2026.
- Who are Corcept Therapeutics's competitors?
- Corcept Therapeutics's key competitors include Xeris Biopharma Holdings, Inc., Corbus Pharmaceuticals Holdings, Inc., Cullinan Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Corcept Therapeutics partner with?
- Corcept Therapeutics's notable partners include Curant Health Georgia, LLC, Syneos Health, Medpace Research, and others.
- Where is Corcept Therapeutics headquartered?
- Corcept Therapeutics is headquartered in United States of America and employs approximately 352 people. It has been publicly traded since 2004.
